O2 RegenTech is advancing OXAID™, a proprietary oxygenating wound dressing intended to enhance healing of chronic wounds by providing oxygen, moisture and bacterial protection. The company holds pending patents licensed from The University of Akron. Leadership is headed by Dr. Andreas Inmann, President & CEO. O2 RegenTech has been awarded grants to fund R&D, including an NSF SBIR and an NIH STTR. The company also received funding from the Ohio Third Frontier Technology Validation and Startup Fund. These awards support continued development and validation of the OXAID™ technology.

Total raised

$1M

Funding rounds

3

Latest round

Grant

Latest activity

Jan 2017